A Phase Ⅱa Study of the Safety, Tolerability and Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis

NCT06474442 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Herpes Simplex Virus Type I Stromal Keratitis

Interventions

GENETIC: BD111 Injection (investigational new drug)
COMBINATION_PRODUCT: Triple-drugs therapy of HSV-1 stromal keratitis

Sponsor

Shanghai BDgene Co., Ltd.